Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection (Hepatology 2013)
http://www.natap.org/2013/HBV/052513_05.htm
Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection; Does Hepatitis B Treatment Reduce the Incidence of Hepatocellular Carcinoma?
Editorial.........http://www.natap.org/2013/HBV/072213_01.htm
Chen et al.5 found a dose-response relationship between pretreatment serum HBV DNA levels and the development of HCC.
In conclusion, in our study we observed the effect of HCC risk among HBV-infected patients treated by ETV by comparing them with a group of NA-naïve patients. We followed these Japanese patients for a relatively long period of time and compared them with a large pool of untreated control patients. In this longterm study among Japanese patients, ETV significantly reduced the incidence of HCC among chronic HBV-infected patients, and was more prominent among patients at higher risk for HCC.
-- All three risk score scales showed that ETV significantly reduced HCC incidence in patients with a higher risk (risk score >/= 12, P = 0.006; risk score
>/= 82, P = 0.002; medium risk, P = 0.062; high risk, P < 0.001).
